Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study

To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment of OLP and RAS. The stu...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-04, Vol.16 (4), p.e0249862
Main Authors: Rogulj, Ana Andabak, Z Alajbeg, Iva, Brailo, Vlaho, Škrinjar, Ivana, Žužul, Ivona, Vučićević-Boras, Vanja, Alajbeg, Ivan
Format: Article
Language:English
Subjects:
Antibiotics
Aphthous stomatitis
Biology and Life Sciences
Corticoids
Corticosteroids
Criteria
Dental materials
Dental restorative materials
Dentistry
Double-blind studies
Drug therapy
Health services
Hematology
Hormones
Hospitals
Hypersensitivity
Immunodeficiency
Immunosuppressive agents
Inflammation
Inflammatory bowel diseases
Intestine
Lichen planus
Medical treatment
Medicine
Medicine and Health Sciences
Mineral oils
Mouthwashes
Oral diseases
Oral hygiene
Pain
Patients
Physical Sciences
Physiological aspects
Pregnancy
Quality of life
Questionnaires
Skin diseases
Spectrophotometry
Steroid hormones
Steroids
Stomatitis
Stomatitis, Aphthous
Testing
Toothpaste
Topical medication
Vitamin B12
Vitamin D3
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the effectiveness of non-aromatic very rich in steranes (NAVS) naphthalan in the treatment of oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS). Null hypothesis was that there would be no difference between NAVS and topical steroids in the treatment of OLP and RAS. The study consisted of two sub-trials conducted as randomized, double-blind controlled studies: first included OLP patients and second patients with RAS. Patients received either NAVS or 0.05% betamethasone dipropionate. Primary outcomes were activity score (OLP patients), No of lesions and lesion diameter (RAS patients) and pain intensity (VAS) while secondary outcome included the impact of the disease on quality of life assessed by Oral health impact profile (OHIP 14). No significant differences in terms of OLP clinical signs (p = 0.84, η2 = 0.001) and responses on the OHIP-14 (p = 0.81, η2 = 0.002) or on VAS (p = 0.14, η2 = 0.079) between NAVS and betamethasone groups were observed. In RAS patients, no significant differences between the groups in terms of lesion number (at days 3 and 5, p = 0.33 and p = 0.98, respectively), lesion diameter (days 3 and 5, p = 0.24 and p = 0.84, respectively) were observed. However, in NAVS group a significant reduction of lesions diameter was observed on the 3rd day, while in betamethasone group a significant reduction in lesions diameter was evident only after the 5th day. No significant differences in VAS (p > 0.05) and the OHIP-14 (p > 0.05) between groups were found. No evidence of differences between the two compared interventions was found. Retrospective registration of this trial was conducted in ClinicalTrials.gov on September 30, 2016; trial registration number: NCT02920658. https://clinicaltrials.gov/ct2/show/NCT02920658?term=NAVS&draw=2&rank=4.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0249862